Company intelligence / Profile preview

Alertix

Ownership: Private
Development stage: Commercial

Overview

Alertix has developed a unique, patented immunochemical assay to detect thymidine kinase 1 (TK1) in animal blood serum. This enables early diagnosis of both solid and blood cancers in companion animals. The test is simple, requiring only a blood sample, and can detect tumor growth before clinical symptoms appear. The dog test is entering the market; cat and horse tests are under development[2][3].

Therapeutic areas: OncologyHematology
Modalities: Device (diagnostic assay)Antibody (immunochemical detection method)
Industry: Protein Biomarker Diagnostics

Drug pipeline

3 assets

PrediPet Canine

Commercial

Indications: Cancer in dogs

2 more assets in the full pipeline.

Request access →

Partnerships

Swedish University of Agricultural Sciences (SLU), Uppsala

Beyond the preview

Go deeper on Alertix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alertix.

Explore the full profile